MUMAK SpotLight of the week: Five stocks in focus

The ongoing earnings season once again shows how differently operational strength, valuation, and short-term price reactions can turn out. Eli Lilly and Palantir are growing exceptionally strongly. Rheinmetall benefits from the expansion of European defense capabilities, Bayer combines operational progress with an improved chart pattern, and Revolution Medicines is approaching a critical regulatory milestone with Daraxonrasib.

Eli Lilly increased revenue in the second quarter of 2026 by 48% to $23.0 billion. Adjusted net income rose by 32% to $7.5 billion, adjusted earnings per share by 33% to $8.38.

The main growth drivers remained Mounjaro and Zepbound. Mounjaro increased by 91% to $9.9 billion, Zepbound by 46% to $4.9 billion. Together, both drugs accounted for almost two-thirds of group revenue. International business developed particularly dynamically, with Mounjaro revenue rising by 172%.

Management raised the revenue guidance for 2026 from previously $82 to $85 billion to $85 to $87 billion. At the same time, positive Phase 3 data for Retatrutid and the US regulatory submission of the oral GLP-1 therapy Orforglipron strengthen the long-term pipeline.

Eli Lilly confirms its position as one of the highest-quality growth companies in the global pharmaceutical sector. High demand, international expansion, and the strong pipeline create an attractive long-term foundation. However, after the initially positive market reaction, rapid profit-taking followed. The further development of the chart pattern therefore remains decisive.

Rheinmetall increased revenue in the first half by 39% to €5.227 billion. Operating income rose by 74% to €786 million, while the operating margin improved from 12.1% to 15.0%.

The second quarter was particularly strong. Revenue increased by 69% to €3.289 billion, operating income by 115% to €562 million. At the same time, the order backlog increased from €56.0 to €80.5 billion.

Operating free cash flow, however, had a negative impact, deteriorating to minus €1.616 billion. After the cancellation of the F126 frigate program, Rheinmetall also lowered its revenue guidance for 2026 to €13.7 to €14.2 billion. The target margin of around 19% remains in place.

Rheinmetall continues to benefit from a structural growth market and a historic order backlog. However, the negative free cash flow and the canceled frigate program show that political decisions and the execution of expansion remain important risks. The analysis result of 4 out of 5 MUMAKS reflects this relationship between quality and risk.

Bayer combines a more stable operational development with a significantly improved chart pattern. Rising group revenue, improved operating income, progress at Crop Science, and the growth of Nubeqa™ and Kerendia™ strengthen the fundamental position.

With the quarterly results, the stock achieved a dynamic GAP breakout above the area of around €49. The zone between €45 and €46 was subsequently defended as support. The next important resistance is at around €53.30. RSI, MACD, and the widening Bollinger Bands also provide constructive signals.

At Bayer, there is currently the greatest alignment of the MUMAK® analysis levels. That is why the company receives the RED HOT CHILI™ MUMAK this week. 🔥📈 The biggest risk remains the glyphosate litigation in the US. Unexpected court decisions could burden the improved fundamental and technical picture at any time.

Palantir increased revenue in the second quarter by 93% to $1.935 billion. Adjusted operating income rose by 159% to $1.20 billion, free cash flow by 114% to $1.22 billion.

US business developed particularly dynamically. Revenue with commercial customers rose by 149%, that with government customers by 90%. For 2026, Palantir now expects revenue of $8.150 to $8.158 billion and growth of around 82%.

The stock reacted with a price jump of 29.45%. The breakout was accompanied by high trading volume and a positive MACD signal. At the same time, the RSI reached the overbought area.

Palantir combines exceptional growth with high profitability and strong free cash flow. The biggest risk remains the ambitious valuation with an expected P/E ratio of around 106. After the strong price increase, short-term profit-taking or consolidation is possible at any time.

Revolution Medicines is developing Daraxonrasib, a promising therapy against RAS-dependent cancers. In the Phase 3 study RASolute 302, the drug increased median overall survival in pretreated metastatic pancreatic cancer from 6.7 to 13.2 months. The risk of death was reduced by 60% compared to chemotherapy.

The FDA has accepted the marketing application, and the EMA is also reviewing the drug. With cash and investments of $3.94 billion, financing is solid. At the same time, capital requirements are rising significantly: the spending guidance for 2026 was raised to $2.1 to $2.2 billion.

Technically, the stock is attempting to overcome resistance at around $194. A confirmed breakout could open further potential, while below $185 the correction risk would increase.

Revolution Medicines has strong clinical data and significant long-term potential. At the same time, the company is not yet generating recurring product revenue and is already ambitiously valued. The result of 4 out of 5 MUMAKS therefore takes into account both the quality of the pipeline and the significant regulatory and commercial risks.

The five companies represent different structural growth themes. Eli Lilly benefits from the boom in diabetes and obesity therapies. Rheinmetall is at the center of European defense expansion. Bayer shows operational stabilization and new technical momentum. Palantir is growing rapidly with AI and data platforms, while Revolution Medicines is on the verge of a potential breakthrough in precision oncology.

At the same time, the risks remain clearly visible: high expectations at Eli Lilly and Palantir, political headwinds and weak free cash flow at Rheinmetall, glyphosate risks at Bayer, and regulatory and commercial uncertainties at Revolution Medicines.

From the perspective of the UMBRELLA Strategy, all five companies confirm interesting long-term investment stories. However, the alignment of fundamental data, market sentiment, and chart technicals remains decisive. Reactions based on the MUMAK® methodology are therefore expressly reserved and strongly dependent on further chart development.